Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,517.30 15.65 0.09%
S&P 500 1,881.19 5.80 0.31%
NASDAQ 4,153.94 26.97 0.65%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013



  Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on
                                July 31, 2013

Conference Call and Webcast to Follow

PR Newswire

WASHINGTON, July 29, 2013

WASHINGTON, July 29, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda)
(NASDAQ: VNDA), a biopharmaceutical company focused on the development and
commercialization of products for the treatment of central nervous system
disorders, today announced it will release results for the second quarter of
2013 on Wednesday, July 31, 2013, before the market opens.

The Company will host a conference call at 10:00 AM ET on Wednesday, July 31,
2013, during which Vanda management will discuss the financial results.  To
participate in the conference call, please dial 1-888-895-5479 (domestic) or
1-847-619-6250 (international) and use passcode 35347357.

The conference call will be broadcast simultaneously and archived on the
Company's website, www.vandapharma.com.  Investors should go to the website at
least 15 minutes early to register, download, and install any necessary audio
software.

A replay of the call will be available on Wednesday, July 31, 2013, beginning
at 12:00 PM ET and will be accessible until Wednesday, August 7, 2013, at 5:00
PM ET.  The replay call-in number is 1-888-843-7419 for domestic callers and
1-630-652-3042 for international callers.  The passcode number is 35347357.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the
development and commercialization of products for the treatment of central
nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please
visit www.vandapharma.com.

Company Contact:
Jim Kelly
Senior Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

SOURCE Vanda Pharmaceuticals Inc.

Website: http://www.vandapharma.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement